Tehran University of Medical Sciences

Science Communicator Platform

Share By
Long Covid in Patients With Multiple Sclerosis Treated With Rituximab: A Report of Two Cases



Tabarsi P ; Mohamadnia A ; Shahabinejad P ; Haseli S ; Askari E ; Bahrami N ; Shafaghi S ; Hajimoradi M
Authors

Source: Tanaffos Published:2025

Abstract

COVID-19 symptoms may persist for more than 12 weeks in some infected patients, a condition described as long COVID-19 in these cases. These patients have symptoms attributed to impairment of multiple organs. Scientists have discovered the lengthy COVID-19 etiology, risk factors, and treatments. It has been observed that immunosuppression may prolong COVID-19 symptoms. Patients with multiple sclerosis (pwMS) are generally treated with disease-modifying treatments, which suppress the immune system and predispose patients to infections like COVID-19. Also, these drugs may increase not only the morbidity and mortality of infection but also the risk of developing long COVID-19 in these patients. We have described two cases of multiple sclerosis patients who were diagnosed with long COVID-19. Both patients were under treatment with rituximab, so we discussed treatment choices and strategies for pwMS patients under rituximab who had symptoms of long COVID. Our data would further add to the information on managing long COVID-19 in pwMS under treatment with rituximab. © 2025 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran.
Related Docs
View other Related Docs
1. Evaluation of the Rate of Covid-19 Infection, Hospitalization and Death Among Iranian Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2020)
2. The Contributory Role of Lymphocyte Subsets, Pathophysiology of Lymphopenia and Its Implication As Prognostic and Therapeutic Opportunity in Covid-19, International Immunopharmacology (2021)
3. Clinical Characteristics, Laboratory Findings, Radiographic Signs and Outcomes of 61,742 Patients With Confirmed Covid-19 Infection: A Systematic Review and Meta-Analysis, Microbial Pathogenesis (2020)
Experts (# of related papers)
View all Related Experts
Abdolreaza Naser Moghadasi (3)
Seyed Ahmad Seyed Alinaghi (3)
Other Related Docs
4. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)
5. A One Year Follow of Patients With Multiple Sclerosis During Covid-19 Pandemic: A Cross-Sectional Study in Qom Province, Iran, Multiple Sclerosis and Related Disorders (2022)
6. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)
7. Prevalence and Complication of Covid-19 in Patients With Ankylosing Spondylitis (As) and Its Relationship With Tnf-A Inhibitors, Immunity# Inflammation and Disease (2023)
8. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)
9. Late Complications of Covid-19; a Systematic Review of Current Evidence, Archives of Academic Emergency Medicine (2020)
10. Potential Role of Interferons in Treating Covid-19 Patients, International Immunopharmacology (2021)
11. Risk Factors for Adverse Outcomes of Covid-19 Patients: Possible Basis for Diverse Responses to the Novel Coronavirus Sars-Cov-2, Life Sciences (2021)
12. Immunomodulatory-Based Therapy As a Potential Promising Treatment Strategy Against Severe Covid-19 Patients: A Systematic Review, International Immunopharmacology (2020)
13. Immunology, Immunopathogenesis and Immunotherapeutics of Covid-19; an Overview, International Immunopharmacology (2021)
14. A Pharmacology-Based Comprehensive Review on Medicinal Plants and Phytoactive Constituents Possibly Effective in the Management of Covid-19, Phytotherapy Research (2021)
15. Characteristics and Management of Multiple Sclerosis Patients During the Omicron Era: Is There a Concern About the Ms Course in the Face of the New Variant of Covid-19?, Neurological Sciences (2023)
16. The Clinical Outcomes of Covid-19 in Hiv-Positive Patients: A Systematic Review of Current Evidence, Immunity# Inflammation and Disease (2021)
17. Covid-19 in Patients With Cancer, Advances in Experimental Medicine and Biology (2021)
18. The Immune System As a Target for Therapy of Sars-Cov-2: A Systematic Review of the Current Immunotherapies for Covid-19, Life Sciences (2020)
19. Myasthenia Gravis Associated With Novel Coronavirus 2019 Infection: A Report of Three Cases, Clinical Neurology and Neurosurgery (2021)
20. Clinical Features and Outcomes of Patients With Myasthenia Gravis Affected by Covid-19: A Single-Center Study, Clinical Neurology and Neurosurgery (2022)